Finding the right book can make a big difference, especially when you’re just starting out or trying to get better. We’ve ...

SAN FRANCISCO -- One new startup is called Recursive with an "e." Another is called Ricursive with an "i." They are trying to do the same thing: Build artificial intelligence that can improve itself ...

Who do you think would win a fight between a python and a crocodile in Florida? Generally, we would look to real-life examples for clues, but surprisingly, there isn’t very much of that. While there ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

It’s happened to all of us: you find the perfect model for your needs — a bracket, a box, a cable clip, but it only comes in STL, and doesn’t quite fit. That problem will never happen if you’re using ...

On CNBC's “Mad Money Lightning Round,” on Thursday, Jim Cramer said Recursion Pharmaceuticals (NASDAQ: RXRX) has been “horrendous” and he does not like to recommend horrendous stocks. On the earnings ...

Monday - Friday, 6:00 - 7:00 PM ET It's that time again! "Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Is Mojo still a contender for Python’s data science crown? AI and machine learning outside of Python There’s no question Python is the default choice for machine learning and data science. That ...

Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...